3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
3
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Breast
1
Conditions
Pain
6
Neoplasms
3
Neoplasm Metastasis
2
Cancer Pain
2
Breast Neoplasms
2
Wounds and Injuries
1
Pleural Effusion, Malignant
1
Pain, Postoperative
1
Mucositis
1
Lung Neoplasms
1
Leiomyoma
1
Ileus
1
Head and Neck Neoplasms
1
Agnosia
1
Interventions
Cisplatin
131
Cetuximab
80
Radiotherapy
76
Docetaxel
59
Carboplatin
46
pembrolizumab
45
Paclitaxel
44
Fluorouracil
42
Radiotherapy, Intensity-Modulated
35
Drug Therapy
17
Radiation
14
Nivolumab
14
Gefitinib
14
Gemcitabine
13
Surgical Procedures, Operative
12
Oxaliplatin
11
Erlotinib Hydrochloride
11
130-nm albumin-bound paclitaxel
11
Pemetrexed
10
Celecoxib
10
Capecitabine
10
Bevacizumab
10
tislelizumab
9
Filgrastim
9
Amifostine
9
Albumin-Bound Paclitaxel
9
durvalumab
7
atezolizumab
7
Chemoradiotherapy
7
toripalimab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Head and Neck Neoplasms
×
Morphine
×
Clear all
NCT05800834
2023-09-28
MorphineGEL
Instituto Nacional de Cancer, Brazil
Phase 2
Unknown
106 enrolled